Avia Pharma and Dr Pfleger have entered into a long-term license agreement for Spasmex (Trospium) and Nyvigan (Nystatin). The license for Spasmex covers Sweden and Norway and the license for Nyvigan covers all Nordic countries.
Spasmex is a well-known product for over-active bladder and is sold in many European countries. Nyvigan is a product for vaginal candidiasis that is also sold in many countries.
“We are very pleased that Dr Pfleger has chosen Avia Pharma to launch these products in the Nordics. Spasmex and Nyvigan will strengthen our position within gynecology and urology” says Jacob Calmvik, CEO of Avia Pharma